Breast cancer ICD 10 coding does not depend on one code, it is rather four decisions a coder has to make. The first decision is where in the breast, it is located, and which side. Both answers sit inside the C50 family. C50.911 is the right breast female code. The second decision is that it is in situ or invasive. D05 for in situ and C50 for invasive carcinoma. Both of these cannot come on a claim together. The third decision is about the receptors which are a part of the claims as Z17 codes beside C50. This is what a payer wants before approving the targeted therapy. The fourth decision is about the history of breast cancer ICD 10, which is Z85.3. This article tells the reader about the diagnosis codes and the claim pairings that lead to claim denials.
How a C50 Code Is Built: Site, Sex, Side
Every ICD 10 breast cancer code in the FY 2027 code set starts with C50 (malignant neoplasm of breast) and then three characters are added. Each character is a question that should be answered by the doctor’s note. The 4th character shows the “where.” Nipple and areola (C50.0), central portion (C50.1), the four quadrants (C50.2 upper-inner, C50.3 lower-inner, C50.4 upper-outer, C50.5 lower-outer), axillary tail (C50.6), overlapping sites (C50.8), or unspecified site (C50.9). The 5th character is about the sex or who: 1 for female and 2 for male. The 6th one is the side: 1 right, 2 left, and 9 unspecified.
| Code | Means | When |
|---|---|---|
| C50.911 | Unspecified site, right female breast | Side known, quadrant not documented |
| C50.912 | Unspecified site, left female breast | Same, left |
| C50.919 | Unspecified site, unspecified female breast | Neither side nor site documented; rarely defensible |
| C50.411 / C50.412 | Upper-outer quadrant, right / left | Quadrant and side documented (most common site) |
| C50.921 / C50.922 | Unspecified site, male breast, right / left | Male patient |
| C50.A1 / C50.A2 | Malignant inflammatory neoplasm, female / male | Inflammatory breast cancer documented |
| C79.81 | Secondary malignant neoplasm of breast | Metastasis to the breast from another primary |
In Situ vs. Invasive: D05 and C50
What does the pathology report answer before anything else? Has the cancer come out of the duct or lobule it started in. If it has not come out, it is in situ and the code is D05. If it has come out of the duct, it is invasive and the code is C50. Ductal carcinoma in situ (DCIS) is D05.1 and lobular carcinoma in situ (LCIS) is D05.0, each with a side. There is an Excludes1 scenario important to discuss. D05 carries an Excludes1 against C50. This shows that in situ and invasive codes for the same breast cannot be used on the same claim.
Once the cancer is invasive, ICD-10-CM does not care about the type of the cell. C50 carries both invasive ductal/lobular carcinoma. The code does not change between them. The same applies to the grade and TNM stage. Neither possess any character in the diagnosis code. One important thing to discuss here is that in situ and invasive are different families, their history codes are also different.
| Pathology says | Code family | Note |
|---|---|---|
| DCIS, right | D05.11 | In situ; not C50 |
| LCIS, left | D05.02 | In situ; not C50 |
| Invasive ductal carcinoma, right, UOQ | C50.411 | Histology not coded |
| Invasive lobular carcinoma, left, unspecified site | C50.912 | Same code family as ductal |
| DCIS with microinvasion | C50.- | Invasive component governs; query if unclear |
| Grade 3, T2 N1 M0 | No code | Documentation and registry; drives necessity, not the ICD-10 code |
Receptor Status: The Z17 Codes That Go With C50
Why do receptor codes exist? First, we need to understand what the pathology report carries. The report has three results that will decide the treatment. Estrogen receptor (ER), progesterone receptor (PR), and HER2. These results are placed on the claim form as Z17 codes according to the ICD-10-CM. The receptor codes are just the results from the pathology report and the treatment is decided on the basis of these results. If the report says ER-positive or PR-positive, the cancer is fed by hormones. Drugs are recommended to block these hormones. If it is HER2-positive cancer, the drug is used that targets the HER2.
A case where all the three results discussed above are negative is called a “triple-negative.” Neither drug type applies, so chemotherapy comes in. The payer that approves the drugs need to see the result that justifies it. ICD-10-CM gives each answer in the code Z17. The table below shows it:
| Pathology says | Code(s) |
|---|---|
| ER+ | Z17.0 |
| ER− | Z17.1 |
| PR+ / PR− | Z17.21 / Z17.22 |
| HER2+ / HER2− | Z17.31 / Z17.32 |
| “Hormone receptor positive” only, no ER/PR split | Z17.41 |
| ER+, PR+, HER2− | Z17.0 + Z17.21 + Z17.32 |
| Triple-negative | Z17.1 + Z17.22 + Z17.32 |
Active Cancer vs. History of Breast Cancer: Z85.3
The difference can be understood with two phrases: “has cancer” and “had cancer.” If the claim says that the patient has cancer, it is C50 and if it says that the patient had cancer, it is Z85.3. But let’s understand when the Z85.3 is allowed. It is allowed when the three things are true: the tumor was removed or destroyed, no treatment is being provided to treat the cancer anymore, and there is no sign of cancer left. If any one of these three things is false, C50 remains there.
There is a trap that should be discussed here. Women with hormone-positive cancer are often prescribed a daily pill for a long time, five to ten years. This pill is the treatment for cancer. In this case, the second condition (no treatment is being provided to the patient) becomes false. So, C50 will stay there for five to ten years. The guideline mentions this clearly: the cancer code is used “until treatment is completed.”
There are some other codes that create confusion, Z86.000 for history of in situ (DCIS or LCIS). Once the DCIS is treated, it is not Z85.3 because DCIS was never a C50 cancer. Z80.3 is family history, the mother had it but the patient did not. Z15.01 is genetic risk with no cancer. The table below shows some details about the situation and the codes used:
| Situation | Code(s) |
|---|---|
| Lumpectomy done, on anastrozole, year 3 | C50.411 (active) + Z17.0 etc. |
| Lumpectomy, radiation and endocrine therapy all completed, no disease | Z85.3 (+ Z08 on the follow-up visit) |
| Chemo infusion visit | Z51.11 first, C50.- second, Z17 codes |
| Mastectomy 6 years ago, surveillance only | Z85.3 + Z90.11/Z90.12 |
| DCIS treated, no disease | Z86.000 |
| Mother and sister had breast cancer, patient does not | Z80.3 |
| BRCA1 positive, no cancer, discussing prophylactic surgery | Z15.01 (Z40.01 on the surgery encounter) |
Before the Diagnosis: N63, N64.4 and R92
There are many visits before the cancer is diagnosed. A patient feels a lump, a mammogram is read, a biopsy is done. When all these visits are happening, the claim cannot say that it is “cancer.” The reason behind it is that there is no confirmation. The claim only says what is confirmed, like a lump or something mammogram showed. There are some codes related to finding the problem.
N63, a lump: The code says where the lump is and it is breast mass N63. N63.0 if nobody documents the side. N63.1 for the right and N63.2 for the left, with a 5th character for the quadrant. N63.11 means the right upper-outer, N63.12 means right upper-inner, and so on. Breast pain N64.4 and the tabular calls it mastodynia. No side is there in the code. R92 is what the mammogram showed. Dense breast / abnormal mammogram R92 is based on the report. The table shows more of what is the encounter and the code selected:
| Encounter | Code |
|---|---|
| Routine screening mammogram, no symptoms | Z12.31 |
| Palpable lump, right upper-outer quadrant | N63.11 |
| Breast pain, no mass | N64.4 |
| Callback after screening: microcalcifications | R92.0 |
| Heterogeneously dense breasts on report | R92.33- (laterality per tabular) |
| Biopsy result: invasive carcinoma | C50.- replaces N63/R92 |
Breast Cancer Documentation Requirements for Coding
This section is based on a scenario where a 58-year-old woman is diagnosed. Every line is a moment and we will walk through six moments to understand six items.
- Side and quadrant. The radiology report says that 1.4cm mass, left breast and upper outer quadrant. After some weeks, the oncologist’s note says “left breast cancer, s/p lumpectomy.” Now, the coder sees this note only, the claim gets C50.912 (left, site unspecified). The radiology report mentioned the quadrant but the coder only checked the note.
- In situ or invasive, with the pathology date. The patient’s first biopsy tells this story: “DCIS, high grade.” The surgical pathology that comes after lumpectomy says this: “DCIS with a 2mm focus of invasive ductal carcinoma.” What happened between the two reports? The code shifted from D05.12 to C50.412. Now, if the coder never reads the surgical pathology and only files from the biopsy report, the invasive cancer never comes on the claim.
- Receptor results, three of them written separately. The pathology report says ER 95%, PR 80%, HER2 negative. The codes are Z17.0, Z17.21, Z17.32. The oncologist’s note has this summary: HR+ disease. What would happen if the coder only saw the summary? The only code is Z17.41 and the HER2 result is absent from the claim entirely. At the payer’s end, the approval of the drug is based on Z17.32 and it is not there.
- Current treatment, including the pill. Eighteen months ago, surgery and radiation were finished. The follow-up note said: doing well, no complaints, continue the anastrozole (pill). The last thing about the pill is what makes the code C50.412 and not Z85.3. If the last part was not there and the note only mentioned doing well and no complaints, the coder finds nothing about the ongoing treatment and could switch to the history code way earlier.
- Surgical history, with side. She is seen with a new lump on the right after two years. The note has to say “s/p left lumpectomy.” At this point, the coding team knows that the left breast is treated and C50.412 is active while she is on the pill. The right lump is a new finding here (N63.1-). So, there is no confusion between the codes.
- Certainty wording on imaging. The mammogram report says: suspicious for malignancy, BI-RADS 4, biopsy recommended. When it says suspicious, this is not cancer. The right side stays N63.1- or R92 until the biopsy says it is carcinoma. If the coder reads ‘suspicious for malignancy’ and files C50.411, that puts a cancer diagnosis on a patient who may not have one.
Why Breast Cancer Claims Get Denied
This section elaborates the reasons behind the cancer claim denials. The columns of the table clearly show what is on the claim, what tends to come back, and the root cause of denials.
| What’s on the claim | What tends to come back | Root cause |
|---|---|---|
| C50.919, report says left UOQ (upper outer quadrant) | Specificity edit / audit | Side and site documented but not coded |
| Z85.3 while patient is on tamoxifen | Audit; endocrine therapy claim questioned | History code during active treatment (I.C.2.m) |
| C50.- years after treatment ended, no disease | Audit exposure | Active code where Z85.3 belongs |
| D05.11 + C50.911 same visit | Edit | Excludes1 pair |
| Z17.0 with no C50 on the claim | Edit | Code-first note not followed |
| Targeted-therapy drug with no Z17.3- code | PA pended / denied | Receptor status not on the claim (payers typically check) |
| Z12.31 on a mammogram ordered for a lump | Denial as screening | Diagnostic encounter coded as screening |
| C50.- listed first on a chemo infusion visit | Edit | Z51.11 should be first (I.C.2.e.2) |
Concluding Remarks on Breast Cancer ICD-10 Coding
The coding for breast cancer diagnosis comes down to a few decisions at every patient visit. Which side, in situ or invasive, what the three receptors said, whether the treatment is ongoing or ended, and why the patient came for the visit that day. The chart has all the answers. One thing important to know is that these answers change over time. Handing over claims to specialists helps oncologists focus on patient care. MedCare MSO’s oncology billing services cover breast cancer coding, receptor-status reporting and the claim review that catches a history code during active treatment.
